Healthcare Review: PTCT, HLF ALQA, ARIA, ADHD

Alcobra Ltd(NASDAQ:ADHD) tanked 53% on huge volume in response to its announcement of results from a 297-patient Phase 3 trial of Metadoxine Extended Release (MDX) in adults patients with Attention Deficit Hyperactivity Disorder (ADHD). It appears that the company excluded four undesirable responses from its Intent To Treat (ITT) population in order to achieve the desired statistical outcome.

1 2
View single page >> |

Disclosure: This article contains information and opinions based on data obtained from reliable sources, which is current as of the publication date, and does not constitute a recommendation ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.